Literature DB >> 3322569

Classic migraine: effective prophylaxis with metoprolol.

P Kangasniemi1, A R Andersen, P G Andersson, N E Gilhus, C Hedman, M Hultgren, S Vilming, J Olesen.   

Abstract

Metoprolol slow-release tablets (Durules), 200 mg, given once daily in the morning were compared with placebo in the prophylaxis of classic migraine. The trial comprised eight Scandinavian neurologic centres and was designed as a double-blind cross-over study with 4 weeks' run-in, four weeks washout, and 8 weeks of either treatment. Seventy-seven patients with two to eight migraine attacks per month were entered in the trial, and 73 completed it. A total of 1119 attacks with aura symptoms and 374 without were recorded. Metoprolol was significantly better than placebo with regard to the total frequency of attacks (1.8 versus 2.5 attacks/4 weeks), mean duration of attacks (6.0 versus 8.0 h/attack), mean global rating, and consumption of analgesics per attack. Similar differences could be shown for attacks with aura symptoms alone, except for the duration of attacks. Metoprolol is the first drug for which a prophylactic effect in classic migraine has been convincingly demonstrated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3322569     DOI: 10.1046/j.1468-2982.1987.0704231.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Migraine with aura: conventional and non-conventional treatments.

Authors:  Giovanni D'Andrea; Davide Colavito; Maurizio Dalle Carbonare; Alberta Leon
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

3.  Preventive pharmacologic treatments for episodic migraine in adults.

Authors:  Tatyana A Shamliyan; Jae-Young Choi; Rema Ramakrishnan; Jennifer Biggs Miller; Shi-Yi Wang; Frederick R Taylor; Robert L Kane
Journal:  J Gen Intern Med       Date:  2013-04-17       Impact factor: 5.128

Review 4.  Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine.

Authors:  K E Andersson; E Vinge
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.

Authors:  Jeffrey L Jackson; Akira Kuriyama; Yachiyo Kuwatsuka; Sarah Nickoloff; Derek Storch; Wilkins Jackson; Zhi-Jiang Zhang; Yasuaki Hayashino
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

6.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.